Telix Total Stockholder Equity from 2010 to 2024

TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about 85.3 M in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
148.9 M
Current Value
85.3 M
Quarterly Volatility
27.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Telix Pharmaceuticals Limited over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Telix Pharmaceuticals' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Very volatile
   Total Stockholder Equity   
       Timeline  

Telix Total Stockholder Equity Regression Statistics

Arithmetic Mean79,035,153
Geometric Mean65,220,831
Coefficient Of Variation35.20
Mean Deviation10,278,379
Median79,016,000
Standard Deviation27,816,514
Sample Variance773.8T
Range146.8M
R-Value0.09
Mean Square Error826.2T
R-Squared0.01
Significance0.74
Slope573,957
Total Sum of Squares10832.6T

Telix Total Stockholder Equity History

202485.3 M
2023148.9 M
202280 M
20212.2 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity148.9 M85.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.